XNAS · NRSN
+7.37% · +$0.0383 · Vol 290.3K
After hours · updated 16:00:43 ET
NeuroSense Therapeutics Ltd. Ordinary Shares

NeuroSense Therapeutics Ltd. Ordinary Shares

$0.5582
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
NRSN
NeuroSense Therapeutics Ltd. Ordinary Shares
Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Wed Aug 5 · session closed · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is NRSN moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading NRSN catalysts
About NeuroSense Therapeutics Ltd. Ordinary Shares
Listed since
2021
Employees
16
Country
US

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.5100
Day high
$0.6000
Day low
$0.5100
Previous close
$0.5199
52W high
$1.38
-59.55% from high
52W low
$0.4652
10% of range
Market cap
$18.8M
Beta
1.06
Shares out
36.1M
Volume
290.3K
0.96× rel vol
Avg volume
301.5K
VWAP
$0.5555
Price history computed in-house
1W
+16.24%
1M
-19.80%
3M
-36.35%
1Y
-59.55%
YTD
-27.41%
SMA 50 $0.7039 · below
SMA 200 $0.8575 · below
52W position 10%

NRSN overview

Veridion Score
59
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around NRSN.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading NRSN Form 4 filings
Public disclosures

Congress activity in NRSN

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for NRSN in the cached public ledger.

Federal contracts

NRSN contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for NRSN in this window.
Lobbying spend

NRSN lobbying filings, year to date.

Registered lobbying filings matched to NeuroSense Therapeutics Ltd. Ordinary Shares.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for NRSN in this window.
Loading news for NRSN
Analyst ratings
Sovereign unlock shows live analyst consensus for NRSN.
Options
Sovereign unlock shows live options positioning for NRSN.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.